- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04084782
An Internet Mediated Research Study to Assess the Quality of Life of Consumers With Self-reported Fungal Nail Infection (Onychomycosis) During Treatment With Scholl Fungal Nail.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
East Yorkshire
-
Hull, East Yorkshire, United Kingdom, HU78DS
- Recruiting
- RB Health
-
Contact:
- Stephen Fincham, MSc
- Phone Number: 00441482582860
- Email: steve.fincham@rb.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18 years or older
- Consumers who have purchased the product online
- Consumers who are willing to participate in the study
Exclusion Criteria:
- Female consumers who are pregnant or breast feeding
- Participants with Diabetes (Type I or II)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Onychomycosis group
Subjects in this group suffer from onychomycosis of the toenail, who chose to self treat by purchasing the product from an online platform.
|
The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Improvement
Time Frame: 28 days
|
Change in mean total score of the OnyCOE-t™ from baseline to end of inital treatment period. The domains are transformed into 0-100 scale where higher scores indicate better functioning. Changes from baseline of the mean total score will be evaluated with repeated measures t-tests. The questionnaire contains 7 domains: 7-item Toenail Symptoms, containing Symptom Frequency (5 categories: 1 = never, 5 = very often) and Symptom Bothersomeness (5 categories: 1 = not at all bothered, 5 = extremely bothered) 8-item Appearance Problems (4 categories: 1 = very much a problem, 4 = not a problem) 7-item Physical Activities Problems (4 categories: 1 = very much a problem, 4 = not a problem) 1-item Overall Problem (4 categories; 1 = very much a problem, 4 = not a problem) 7-item Stigma (5 categories: 0 = does not describe me at all, 4 = describes me very well) 3-item Treatment Satisfaction scale (5 categories: 1 = very satisfied, 5 very dissatisfied) |
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participant perception of the improvement in healthy appearance of their infected toenail.
Time Frame: Any timepoint up to day 28
|
The participants will be asked to score the statement "My toenail looks healthy" (prior to product use) and "My toenail looks healthier" (at various time points following product application) using the following categories, strongly agree, agree, neither agree nor disagree, disagree, Strongly disagree.
A successful outcome of this measure would be 70% Top 2 Boxes (T2B) (Strongly Agree or Agree) improvement in the healthier appearance of the target toenail at any post baseline assessment compare to Day 1 (prior to initial product application)
|
Any timepoint up to day 28
|
|
Participant perception of improvement in brightness of their infected toenail.
Time Frame: Any timepoint up to day 28
|
The participants will be asked to score the statement "My toenail looks bright" (prior to product use) and "My toenail looks brighter" (at various time points following product application) using the following categories, strongly agree, agree, neither agree nor disagree, disagree, Strongly disagree.
A successful outcome of this measure would be 70% T2B (Strongly Agree or Agree) improvement in the brighter appearance of the target toenail as determined by participant perceived questions at any post baseline assessment compare to Day 1 (prior to initial product application)
|
Any timepoint up to day 28
|
|
Participant perception of the improvement in colour of their infected toenail.
Time Frame: Any timepoint up to day 28
|
The participants will be asked to score the statement "My toenail is its natural colour" (prior to product use) and "My toenail is returning to its natural colour" (at various time points following product application) using the following categories, strongly agree, agree, neither agree nor disagree, disagree, Strongly disagree.
A successful outcome of this measure would be 70% T2B (Strongly Agree or Agree) improvement in the colour of the target toenail as determined by participant perceived questions at any post baseline assessment compare to Day 1 (prior to initial product application)
|
Any timepoint up to day 28
|
|
Participant perception of the improvement in smoothness of their infected toenail.
Time Frame: Any timepoint up to day 28
|
The participants will be asked to score the statement "My toenail looks smooth" (prior to product use) and "My toenail looks smoother" (at various time points following product application) using the following categories, strongly agree, agree, neither agree nor disagree, disagree, Strongly disagree.
A successful outcome of this measure would be 70% T2B (Strongly Agree or Agree) improvement in the smoothness of the target toenail as determined by participant perceived questions at any post baseline assessment compare to Day 1 (prior to initial product application)
|
Any timepoint up to day 28
|
|
Participant perception of improvement of their feelings of embarrassment associated with their infected toenail.
Time Frame: Any timepoint up to day 28
|
The participants will be asked to score the statement "I am feeling embarrassed by the appearance of my toenail" (prior to product use and at various time points following product application) using the following categories, strongly agree, agree, neither agree nor disagree, disagree, Strongly disagree.
A successful outcome of this measure would be 70% of responses show improvement from baseline and are in the T2B (Strongly Disagree or Disagree) in the feelings of embarrassment relating to the appearance of the target toenail as determined by participant perceived questions at any post baseline assessment compared to Day 1 (prior to initial product application)
|
Any timepoint up to day 28
|
|
Individual OnyCOE-t(TM) domain improvement
Time Frame: 28 days
|
Improvement in the mean scores on the individual OnyCOE-t(TM) domains (as detailed in outcome 1 above). The data will be summarised with means, standard deviations, range and 95% confidence intervals, changes from baseline of the mean individual domain score will be evaluated using repeated measures t-tests. |
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Neil Fawkes, MBChB, Reckitt Bencksier, Dansom Lane, Hull
Publications and helpful links
General Publications
- Velasquez-Agudelo V, Cardona-Arias JA. Meta-analysis of the utility of culture, biopsy, and direct KOH examination for the diagnosis of onychomycosis. BMC Infect Dis. 2017 Feb 22;17(1):166. doi: 10.1186/s12879-017-2258-3.
- Sigurgeirsson B, Ghannoum MA, Osman-Ponchet H, Kerrouche N, Sidou F. Application of cosmetic nail varnish does not affect the antifungal efficacy of amorolfine 5% nail lacquer in the treatment of distal subungual toenail onychomycosis: results of a randomised active-controlled study and in vitro assays. Mycoses. 2016 May;59(5):319-26. doi: 10.1111/myc.12473. Epub 2016 Feb 11.
- Christenson JK, Peterson GM, Naunton M, Bushell M, Kosari S, Baby KE, Thomas J. Challenges and Opportunities in the Management of Onychomycosis. J Fungi (Basel). 2018 Jul 24;4(3):87. doi: 10.3390/jof4030087.
- Tosti A, Elewski BE. Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life. J Clin Aesthet Dermatol. 2014 Nov;7(11):25-30.
- Potter LP, Mathias SD, Raut M, Kianifard F, Tavakkol A. The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis. Health Qual Life Outcomes. 2006 Aug 15;4:50. doi: 10.1186/1477-7525-4-50.
- Potter LP, Mathias SD, Raut M, Kianifard F, Landsman A, Tavakkol A. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18(1):46-52. doi: 10.1080/09546630600965004.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NPD89101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis of Toenail
-
Onyx AxiomNot yet recruiting
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
Medical Life Care Planners, LLCNot yet recruitingFungal Infection | Onychomycosis of Toenail | Toenail Infection
-
Vanda PharmaceuticalsActive, not recruitingOnychomycosis of ToenailUnited States
-
Mediprobe Research Inc.Emblation LimitedCompleted
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Erchonia CorporationWithdrawnOnychomycosis of ToenailUnited States
-
DeviceFarm, Inc.CompletedOnychomycosis | Onychomycosis of ToenailUnited States
-
Erchonia CorporationTerminatedOnychomycosis of ToenailUnited Kingdom
-
Hallux, Inc.Active, not recruitingOnychomycosis of ToenailUnited States
Clinical Trials on Fungal Nail Treatment Kit
-
Reckitt Benckiser Healthcare (UK) LimitedIntertekCompletedOnychomycosis of ToenailsUnited Kingdom
-
Reckitt Benckiser Healthcare (UK) LimitedCompletedOnychomycosis of ToenailsUnited Kingdom
-
London School of Hygiene and Tropical MedicineCheikh Anta Diop University, Senegal; Action Contre la FaimCompleted
-
Thomas Jefferson UniversityCompleted
-
Centre Hospitalier de CayenneOswaldo Cruz Foundation; Dr Stephen Vreden (Foundation for Scientific Research... and other collaboratorsCompletedMalaria | Public HealthBrazil, Suriname
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...The Leeds Teaching Hospitals NHS Trust; University of Leeds; European Organisation... and other collaboratorsNot yet recruitingCancer | Palliative Care | SurvivorshipHungary, Italy, France, United Kingdom, Netherlands, Estonia, Serbia, Lithuania, Slovenia, Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Finland, Georgia, Germany, Greece, Ireland, Latvia, Moldova, Republic of, Norwa... and more
-
Second Affiliated Hospital, School of Medicine,...CompletedInfectious KeratitisChina
-
AgNovos Healthcare, LLCActive, not recruitingVertebral Compression Fracture | Vertebral Compression | Compression FractureUnited States
-
University of MichiganDMG Dental Material Gesellschaft mbHCompleted
-
DMG Dental Material Gesellschaft mbHTerminatedCaries | Tooth Sensitivity | Salivary FunctionUnited States